Profile change history

What changed for Insulin glargine-aldy?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Insulin glargine-aldy identity.

9Total events
6Record additions
3Version changes
1Cited source years

Before and after

Preserved version changes

Profile updated

Insulin glargine-aldy profile

We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.

PeptideScanner change date
November 16, 2026
Evidence lane
Profile

Evidence note

Before
FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.
After
Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.

Cited source records

Before
dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026
After
dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026, fda-lantus-label-2023

Claim citations

Before
name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-langlara-approval-2026
After
name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-lantus-label-2023, fda-langlara-approval-2026
Profile status changed

Insulin glargine-aldy profile

We added a plain-language reader guide with cited answers, re-checked the Langlara label, and added the Drugs@FDA record and FDA’s April 2026 approval letter.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
U.S. label record
After
FDA-approved as Langlara

Profile summary

Before
A long-acting insulin analogue. This profile cites a U.S. prescription label.
After
A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes.

Evidence note

Before
The cited DailyMed label identifies Insulin glargine-aldy and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.

Cited source records

Before
dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5
After
dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026

Named organizations

Before
U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]
After
U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]; U.S. Food and Drug Administration [sources: fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026]

Claim citations

Before
name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5
After
name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-langlara-approval-2026
Profile updated

Insulin glargine-aldy profile

We rewrote the profile summary to describe the cited public record more directly. The cited sources and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A long-acting insulin analogue represented by one exact current U.S. prescription-label record.
After
A long-acting insulin analogue. This profile cites a U.S. prescription label.

Collection chronology

Evidence added to PeptideScanner

Browse all 6 connected records →

Showing the latest 6 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 15, 2026.

Record added

Insulin glargine-aldy DailyMed SPL version 6

DailyMed lists Structured Product Labeling version 6 for the reviewed Insulin glargine-aldy label family with a published date of 2026-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
September 21, 2026
Evidence lane
Regulatory
Record added

Insulin glargine-aldy DailyMed SPL version 7

DailyMed lists Structured Product Labeling version 7 for the reviewed Insulin glargine-aldy label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
November 15, 2026
Cited source date
October 19, 2026
Evidence lane
Regulatory
Record added

Insulin glargine-aldy DailyMed SPL version 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
June 2, 2026
Evidence lane
Regulatory
Record added

Insulin glargine-aldy DailyMed SPL version 2

DailyMed lists Structured Product Labeling version 2 for the reviewed Insulin glargine-aldy label family with a published date of 2026-06-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
June 5, 2026
Evidence lane
Regulatory
Record added

Insulin glargine-aldy DailyMed SPL version 5

DailyMed lists Structured Product Labeling version 5 for the reviewed Insulin glargine-aldy label family with a published date of 2026-07-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

PeptideScanner change date
August 22, 2026
Cited source date
July 8, 2026
Evidence lane
Regulatory